ANTONAZZO, IPPAZIO COSIMO

ANTONAZZO, IPPAZIO COSIMO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 77 (tempo di esecuzione: 0.03 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 01 - Articolo su rivista 2016 Antonazzo I. C. +
Raphanus sativus cv. Sango sprout juice decreases diet-induced obesity in sprague dawley rats and ameliorates related disorders 01 - Articolo su rivista 2016 Antonazzo I. C. +
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 01 - Articolo su rivista 2017 Antonazzo I. C. +
Digestibility, toxicity and metabolic effects of rapeseed and sunflower protein hydrolysates in mice 01 - Articolo su rivista 2017 Antonazzo I. C. +
The Burden of Chronic Heart Failure in Primary Care in Italy 01 - Articolo su rivista 2017 Antonazzo I. C. +
Diabetes is associated with decreased migraine risk: A nationwide cohort study 01 - Articolo su rivista 2018 Antonazzo I. C. +
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 01 - Articolo su rivista 2018 Antonazzo I. C. +
Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis 01 - Articolo su rivista 2018 Antonazzo I. C. +
Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis 01 - Articolo su rivista 2018 Antonazzo I. C. +
Drug-induced Kounis syndrome: A matter of pharmacovigilance 01 - Articolo su rivista 2019 Antonazzo I. C. +
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 01 - Articolo su rivista 2019 Antonazzo I. C. +
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 01 - Articolo su rivista 2019 Antonazzo I. C. +
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 01 - Articolo su rivista 2019 Antonazzo I. C. +
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System 01 - Articolo su rivista 2019 Antonazzo I. C. +
Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study 01 - Articolo su rivista 2019 Antonazzo I. +
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 01 - Articolo su rivista 2020 Antonazzo I. C. +
Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution 01 - Articolo su rivista 2020 Antonazzo I. C. +
PCSK9 Inhibitors’ New Users: Analysis of Prescription Patterns and Patients’ Characteristics from an Italian Real-world Study 01 - Articolo su rivista 2020 Antonazzo IC +
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 01 - Articolo su rivista 2020 Antonazzo I. C. +
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system 01 - Articolo su rivista 2020 Antonazzo I. C. +